Bayer AG (OTCMKTS:BAYRY) – Stock analysts at Jefferies Financial Group increased their FY2019 earnings estimates for shares of Bayer in a research note issued on Wednesday, August 15th. Jefferies Financial Group analyst I. Hilliker now expects that the company will post earnings of $2.29 per share for the year, up from their prior forecast of $2.24. Jefferies Financial Group has a “Hold” rating on the stock.

BAYRY has been the subject of a number of other reports. ValuEngine upgraded shares of Bayer from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 28th. DZ Bank restated a “buy” rating on shares of Bayer in a research report on Thursday, May 17th. JPMorgan Chase & Co. restated a “buy” rating on shares of Bayer in a research report on Monday, August 13th. Finally, Zacks Investment Research upgraded shares of Bayer from a “strong sell” rating to a “hold” rating in a research report on Monday, July 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $36.00.

OTCMKTS:BAYRY opened at $22.73 on Thursday. The company has a quick ratio of 2.04, a current ratio of 2.53 and a debt-to-equity ratio of 0.32. The firm has a market cap of $87.95 billion, a price-to-earnings ratio of 11.96, a P/E/G ratio of 2.02 and a beta of 1.15. Bayer has a fifty-two week low of $23.58 and a fifty-two week high of $35.41.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.